The Sudden Departure of FDA Nominee Martin Makary
The health policy world was jolted this week by the abrupt withdrawal of Dr. Martin Makary’s nomination to lead the Food and Drug Administration. Makary, a surgeon and author known for his outspoken criticism of medical bureaucracy, had been President Trump’s pick to overhaul the agency. His departure leaves a void at a critical time, and raises questions about which of his proposed policies will survive.
Why Makary Left
Makary’s exit was driven by a combination of political headwinds and personal calculation. Despite strong backing from conservative health reformers, his nomination faced stiff opposition from key senators, including Senator Bill Cassidy. Cassidy, a physician himself, voiced concerns over Makary’s past stances on vaccine mandates and his promotion of unproven COVID-19 treatments like ivermectin. Rather than endure a grueling confirmation battle that could have damaged his reputation, Makary opted to step aside. The White House accepted his withdrawal, signaling a desire to avoid a protracted partisan fight.
Which Policies Will Stick
Even before his nomination stalled, Makary had been a vocal advocate for several FDA reforms. These included reducing regulatory red tape for drug approvals, increasing transparency in vaccine data, and shifting the agency’s focus toward long-term safety monitoring. While his departure dims the immediate prospects for these changes, some elements may endure as informal priorities within the FDA. For instance, the push for more patient-centric endpoints and real-world evidence in clinical trials already had bipartisan support. However, without Makary at the helm, the pace of reform is likely to slow.
The Acting Replacement: Kyle Diamantas
To fill the leadership void, the administration has appointed Kyle Diamantas as acting FDA commissioner. Diamantas, a longtime FDA official with deep expertise in regulatory science, is viewed as a steady hand during a turbulent period. Unlike Makary, he is not seen as an ideological reformer but rather a pragmatic administrator. His immediate tasks include managing ongoing drug shortage crises, advancing the agency’s review of new gene therapies, and maintaining morale among a workforce rattled by political turmoil. Diamantas’s tenure is expected to be interim, possibly lasting until after the 2026 midterm elections.
Senator Bill Cassidy’s Precarious Position
While Makary’s departure dominated headlines, the political dynamics behind it also spotlighted the tenuous hold Senator Bill Cassidy has on his Louisiana seat. Cassidy, a Republican and a gastroenterologist, has long straddled the line between his medical expertise and partisan loyalty. His role in scuttling Makary’s nomination—along with earlier votes on health secretary RFK Jr.—has left him vulnerable to attacks from both the right and left.
The Primary Challenge Threat
Cassidy’s troubles stem largely from his willingness to cross party lines on high-profile health votes. In 2025, he backed the confirmation of RFK Jr. for Health and Human Services, a move that pleased vaccine-skeptic activists but angered mainstream Republicans. Then, by opposing Makary, he alienated Trump loyalists who saw the nominee as a reform champion. The result is a “mushy middle” that invites primary challengers. In Louisiana’s conservative electorate, any deviation from party orthodoxy is risky. Several potential opponents have already begun laying groundwork, painting Cassidy as a Washington insider out of touch with grassroots values.
Narrow Reelection Prospects
Adding to Cassidy’s worries is the shifting demographic and political landscape of Louisiana. Once a safe Republican seat, it has become more competitive due to court-ordered redistricting that created a second majority-minority district. Cassidy’s own district now includes more Democratic-leaning voters, making a general election win uncertain even if he survives the primary. National Democrats see an opportunity to flip the seat and have signaled they will pour resources into the race. Cassidy’s health care record—including his support for the Affordable Care Act’s Medicaid expansion while in Congress—could be both a strength and a liability, depending on the electorate.
The Interplay Between the Two Stories
The Makary and Cassidy sagas are intertwined in a broader narrative about health politics in America. Makary’s departure underscores the difficulty of enacting sweeping FDA reforms when even a partial endorsement from a sitting senator can derail a nomination. Cassidy’s precarious seat, meanwhile, illustrates how individual votes on health policy can have lasting political consequences. For voters, these developments highlight the delicate balance between expertise and ideology that defines modern governance. As the 2026 election cycle approaches, both Makary’s legacy and Cassidy’s future will remain under the microscope.
This article is based on reporting from Stat News’ “The Readout LOUD” podcast, featuring FDA reporter Lizzy Lawrence. For more on health policy shifts, tune into upcoming episodes.